Citius Pharmaceuticals, Inc. (CTXR)
CIK 1506251 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 27.5M shares as of May 14, 2026 (10-Q). Share count fell from 180.7M to 7.7M between Aug 12, 2024 and Dec 18, 2024, a pattern consistent with a reverse split (roughly 1-for-23); simultaneous issuance can skew the raw ratio, so confirm in the filings. The red bar marks the cliff.
Cash runway
Going-concern warning
auditor flagged substantial doubt
The company itself flagged going-concern doubt in a filing.
Full breakdown: cash runway tool · source filing →
Warrants
| Tranche | Warrants | Exercise price | Term | Notes |
|---|---|---|---|---|
| Warrant | 16.5M | $1.09 | — | FV $5.3M |
| December2025 Offering Investors One | 16.5M | $1.09 | — | — |
| June2025 Offering Investor | 9.8M | $1 | — | — |
| December2025 Citius Oncology Offering | 8.2M | not tagged | — | — |
| December2025 Offering Investors | 7.0M | $0.0001 | — | — |
| July2025 Offering Investors | 6.8M | $1.09 | — | — |
| September2025 Citius Oncology Offering | 5.1M | not tagged | — | — |
| September2025 Offering Investors | 5.1M | $1.09 | — | — |
| Citius Pharmaceuticals Warrants | 4.4M | not tagged | — | — |
| October2025 Offering Investor | 4.0M | $1.4 | — | — |
| Prefunded Warrants | 1.3M | $0.0001 | — | — |
| December2025 Placement Offering Agent | 1.2M | $1.3625 | — | — |
Tranches exactly as the company dimensioned them in its 10-Q filed May 15, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.
Warrants outstanding: 17.6M underlying shares, as reported Jun 30, 2025 (10-Q).
Reported exercise price: $3.91 (aggregate figure as tagged; individual tranches vary).
Balance-sheet fair value of warrants: $13.2M as of Dec 10, 2025.
Rough fully diluted estimate: 45.1M = 27.5M O/S + 17.6M warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.
Convertible notes
No convertible-note facts tagged in the 10-Q filed May 15, 2026. If convertible notes exist, their terms live in exhibit prose for this filer and are not parsed; absence of a tag is not proof of absence. The exhibits are the ground truth.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 27.5M | May 14, 2026 |
| + Warrant (if exercised) | 16.5M | Dec 10, 2025 |
| + December2025 Offering Investors One (if exercised) | 16.5M | Mar 31, 2026 |
| + June2025 Offering Investor (if exercised) | 9.8M | Mar 31, 2026 |
| + December2025 Citius Oncology Offering (if exercised) | 8.2M | Dec 10, 2025 |
| + December2025 Offering Investors (if exercised) | 7.0M | Mar 31, 2026 |
| + July2025 Offering Investors (if exercised) | 6.8M | Mar 31, 2026 |
| + September2025 Citius Oncology Offering (if exercised) | 5.1M | Sep 10, 2025 |
| + September2025 Offering Investors (if exercised) | 5.1M | Mar 31, 2026 |
| + Citius Pharmaceuticals Warrants (if exercised) | 4.4M | Mar 31, 2026 |
| + October2025 Offering Investor (if exercised) | 4.0M | Mar 31, 2026 |
| + Prefunded Warrants (if exercised) | 1.3M | Dec 10, 2025 |
| + December2025 Placement Offering Agent (if exercised) | 1.2M | Mar 31, 2026 |
| Fully diluted estimate | 113.4M | +313.2% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Registered offering capacity on live registrations: $2.9Mfrom the structured fee exhibits; registered is not remaining, takedowns are not subtracted
Last 12 months: 3 executed · 1 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full CTXR workspace